sunitinib malate

Known as: 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide), Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1) 
The orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1992-2018
010203019922018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
BACKGROUND The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuroendocrine tumors in… (More)
  • table 1
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor approved for advanced renal cell carcinoma and… (More)
  • table 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
AIMS To assess the antitumour activity, safety, pharmacokinetics and pharmacodynamics of continuous daily sunitinib dosing in… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Most gastrointestinal stromal tumors (GISTs) exhibit aberrant activation of the receptor tyrosine kinase (RTK) KIT. The efficacy… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE Sunitinib is an oral, multitargeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND Sunitinib malate is a novel multitargeted receptor tyrosine kinase inhibitor with established efficacy in the… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND Since sunitinib malate has shown activity in two uncontrolled studies in patients with metastatic renal-cell carcinoma… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Cancer patients treated with antiangiogenic multitargeted receptor tyrosine kinase (RTK) inhibitors show increased levels of… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2006
Highly Cited
2006
CONTEXT Current treatment options for metastatic renal cell carcinoma (RCC) are limited and there is a need to identify novel and… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2006
Highly Cited
2006
PURPOSE Renal cell carcinoma (RCC) is characterized by loss of von Hippel Lindau tumor suppressor gene activity, resulting in… (More)
Is this relevant?